FCM
NVO

Fourpath Capital Management’s Novo Nordisk NVO Stock Holding History

Fourpath Capital Management’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-5,096
Closed -$352K – 240
2025
Q2 		$352K Buy
5,096
+1,444
+40% +$98.2K 0.06% 172
2025
Q1 		$254K Buy
3,652
+346
+10% +$28.6K 0.04% 192
2024
Q4 		$284K Buy
3,306
+306
+10% +$33.1K 0.05% 184
2024
Q3 		$357K Buy
+3,000
New +$400K 0.07% 166

Other funds holding NVO

Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return
Fayez Sarofim & Co
Fayez Sarofim & Co Houston, Texas $39.1B AUM 15.14% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Fourpath Capital Management's NVO Position: Q3 2025 in Review

Fourpath Capital Management sold out of Novo Nordisk (NVO) in Q3 2025, closing a stake of 5,096 shares — an estimated $352K sold.

Fourpath Capital Management first reported a position in NVO in Q3 2024 and held it in 4 quarters. The position peaked at $357K in Q3 2024. 1,395 funds tracked by Wall St. Rank hold NVO as of Q3 2025.

  • Fourpath Capital Management reported no remaining Novo Nordisk position as of Q3 2025 after selling out during the quarter.
  • Fourpath Capital Management sold 5,096 Novo Nordisk shares in Q3 2025, an estimated $352K.
  • Fourpath Capital Management first reported a position in Novo Nordisk in Q3 2024 and held it in 4 quarters.
  • Fourpath Capital Management's Novo Nordisk position peaked at $357K in Q3 2024.
  • 1,395 funds tracked by Wall St. Rank held Novo Nordisk as of Q3 2025.

Based on Fourpath Capital Management's 13F filing for Q3 2025, filed 14 Oct 2025.